Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy

Abstract

Temozolomide (TMZ), the standard first-line chemotherapy for glioblastoma multiforme (GBM), has been a cornerstone of treatment despite its known limitations. We propose critically assessing TMZ's potential to induce multiple regulated cell death modalities and leveraging their immunogenic properties to develop novel strategies for overcoming the resistance of GBM and enhancing its therapy.

Keywords: ICD; apoptosis; chemotherapy; ferroptosis; glioblastoma; glioma; immunogenic cell death; mixed types of cell death; necroptosis; pyroptosis; resistance mechanisms.